12.07.2015 Views

Boston - American Association for Thoracic Surgery

Boston - American Association for Thoracic Surgery

Boston - American Association for Thoracic Surgery

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

AMERICAN ASSOCIATION FOR THORACIC SURGERYWEDNESDAY MORNINGMAY 13, 20097:00 a.m. EMERGING TECHNOLOGIES ANDTECHNIQUES FORUMBallroom A–C, Hynes Convention Center(5 Minutes Presentation, 7 Minutes Discussion)Moderators: Robert J. McKenna, Lars G. SvenssonT1. The Direct Flow Valve: First in Man Experience with aRepositionable and Retrievable Pericardial Valve <strong>for</strong>Percutaneous Aortic Valve ReplacementHendrik Treede, 1 Jochen Schofer, 2 Thilo Tuebler, 2 Olaf Franzen, 1Thomas Meinertz, 1 Reginald Low, 3 Steven F. Bolling, 4* Hermann Reichenspurner 1*1. Department of Cardiovascular <strong>Surgery</strong>, University Heart Center Hamburg,Hamburg, Germany; 2. Hamburg University Cardiovascular Center, Hamburg,Germany; 3. University of Cali<strong>for</strong>nia Davis, Davis, CA, USA 4. University ofMichigan Hospital, Ann Arbor, MI, USAInvited Discussant: Tomislav MihaljevicOBJECTIVE: Percutaneous aortic valve replacement is a considerable alternative<strong>for</strong> patients carrying a high risk <strong>for</strong> operation. The Direct Flow percutaneous aorticvalve is the first that is not based on stent technology. The stentless tissue valvewith bovine pericardial leaflets is connected to two inflatable rings showing a highflexibility and deliverability. It is immediately competent upon initial inflation.Implantation does not require rapid pacing or cardiac support. The valve is repositionable,retrievable and available in two sizes.METHODS: 31 patients were enrolled in this clinical trial. 9 patients were excludeddue to excessive calcifications or other reasons. A total of 22 patients underwentpercutaneous valve replacement. All patients had a high risk <strong>for</strong> operation (MeanLog. Euroscore 28 ± 7%, mean STS score 24 ± 9%). Mean pre-interventionalgradients were 50 ± 13 mmHg, mean aortic orifice area was 0.55 ± 0.16 cm 2 . Thedevice was placed transfemoral in the left ventricle by a flexible sheath underflouroscopic control. The lower ring was inflated and the valve was positioned inthe LV outflow tract and then pulled against the aortic annulus. After inflation ofthe upper ring valve per<strong>for</strong>mance was controlled and eventual repositioningper<strong>for</strong>med. Polymer media were infused in the rings once correct position wasconfirmed.WEDNESDAYMorning* AATS Member197

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!